In this issue El-Bayoumi and colleagues [1] publish the results of a randomised controlled trial comparing intravenous immunoglobulin (IVIg) with plasma exchange in mechanically ventilated children with Guillain-Barré syndrome (GBS). Any randomised study in an uncommon condition such as GBS deserves serious attention and a study like this in children is especially valuable since almost all previous studies were done entirely in adults [2, 3] . GBS is less common in children and has been said to pursue a milder course, but this is uncertain and there are no known diff erences in its electrophysiology or pathology from GBS in adults so that diff erences in treatment response are not expected. Th e conclusion from previous trials summarised in a Cochrane review was that plasma exchange and IVIg have equivalent effi cacy in terms of improvement in disability after 4 weeks, the primary outcome in the review, duration of ventilation and long-term disability [4] . Furthermore, in the largest trial, adding IVIg after plasma exchange did not make a signifi cant diff erence to any outcome [5] . Despite the effi cacy of IVIg and plasma exchange, cortico steroids are ineff ective, although their use for other coincident medical conditions is not harmful.
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El-Bayoumi and colleagues randomised severely aff ected children with GBS to a standard course of one plasma volume plasma exchange on fi ve consecutive days or a standard IVIg course of 0.4 g/kg infusions also on fi ve consecutive days. Th ey report that the outcome was similarly favourable in both groups but that the duration of mechanical ventilation was signifi cantly shorter in the plasma exchange group (median 11 days, interquartile range 11.0 to 13.0) than in the IVIg group (median 13 days, interquartile range 11.3 to 14.5), a two day diff erence, which is large enough to be perceived as worthwhile if it were a genuine diff erence. However, this result may have been biased by the fact that the assessors were not masked from knowing which regimen the participant had received. Furthermore, in both previous large trials the duration of ventilation was shorter with IVIg than plasma exchange. In the fi rst trial, the median duration of ventilation was 27 days (95% confi dence interval (CI) 13 to 97) in 29 patients treated with IVIg and 34 days (95% CI 12 to 97 ) in 34 patients with plasma exchange [6] . In the second trial, the median duration of ventilation was 26 days (95% CI 18.4 to 38.2) in 44 patients treated with IVIg and 29 days (95% CI 19.1 to 45.9) in 40 patients treated with plasma exchange [5] . Th ere is no easy method for performing a meta-analysis of medians but inspection of these results suggests that there is no signifi cant diff erence in effi cacy of IVIg and plasma exchange for duration of requirement for artifi cial ventilation. In the El-Bayoumi and colleagues trial, no serious adverse events were encountered. However, in fi ve trials for which information was available for the Cochrane review, there were more adverse events in the plasma exchange than the IVIg group [4] . While IVIg is the preferred treatment in many centres because of its convenience, simplicity and greater comfort for the patient, the ElBayoumi and colleagues trial results support the con clusion of the Cochrane review that intravenous immunoglobulin and plasma exchange are equally effi cacious. Plasma exchange is therefore an acceptable treatment for GBS instead of IVIg, especially in resource-poor settings and in an ICU where good facilities for the procedure are readily available.
